175 related articles for article (PubMed ID: 36091128)
1. Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.
Huang Y; Wang J; Hu Y; Cao P; Wang G; Cai H; Wang M; Yang X; Wei Z; Ye X
Front Oncol; 2022; 12():938827. PubMed ID: 36091128
[TBL] [Abstract][Full Text] [Related]
2. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.
Wei Z; Yang X; Ye X; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zou Z; Wen Q
J Cancer Res Ther; 2019; 15(7):1629-1634. PubMed ID: 31939448
[TBL] [Abstract][Full Text] [Related]
3. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
Xu CR; Chen Q; Zhou C; Wu L; Li W; Zhang H; Li Y; Xu F; Xiong J; Wang Q; Zhang H; Jiang Y; Yin H; Wu Q; Dai Q; Hu J; Chen J; Zhang J; Wu G; Yin J; Zhao J; Liu B; Shan J; Sheng L; Chen Q; Han Z; Shi H; Liu Y; Chen J; Wu YL
Transl Lung Cancer Res; 2023 Jan; 12(1):127-140. PubMed ID: 36762057
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC.
Ni X; Han JQ; Ye X; Wei ZG
Onco Targets Ther; 2015; 8():3227-35. PubMed ID: 26604789
[TBL] [Abstract][Full Text] [Related]
8. Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101).
Wang R; Shi M; Ji M; Han Z; Chen L; Liu Y; Lu K; Liu L; Chen B; Zhang X; Miao L; Shu Y
Transl Lung Cancer Res; 2023 Apr; 12(4):786-796. PubMed ID: 37197631
[TBL] [Abstract][Full Text] [Related]
9. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
10. Maintenance treatment of immunotherapy after microwave ablation plus drug-eluting bead bronchial arterial chemoembolization for advanced non-small cell lung cancer: a retrospective single-center cohort study.
Xu S; Bie ZX; Li YM; Qi J; Peng JZ; Li XG
Quant Imaging Med Surg; 2024 May; 14(5):3473-3488. PubMed ID: 38720847
[TBL] [Abstract][Full Text] [Related]
11. Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations.
Wei Z; Ye X; Yang X; Zheng A; Huang G; Li W; Wang J; Han X; Meng M; Ni Y
Oncotarget; 2017 Aug; 8(34):56714-56725. PubMed ID: 28915624
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
Hou X; Shi X; Luo J
Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis.
Wang J; Su S; Li J; Li Y
Front Oncol; 2021; 11():695512. PubMed ID: 34249752
[TBL] [Abstract][Full Text] [Related]
14. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
You R; Xu Q; Wang Q; Zhang Q; Zhou W; Cao C; Huang X; Ji H; Lv P; Jiang H; Lu Y; Jin Y; Li Y; Cheng L; Wang W; Xu H; Zhu X; Yin G
Front Oncol; 2022; 12():816198. PubMed ID: 35982962
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer.
Zhang D; Kong F; Gao F; Li L; Liang Y; Yu M; Zhao L; Wang N; Jia Y
Heliyon; 2024 Jan; 10(1):e22913. PubMed ID: 38148793
[TBL] [Abstract][Full Text] [Related]
17. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X
Med Oncol; 2015 Feb; 32(2):464. PubMed ID: 25572816
[TBL] [Abstract][Full Text] [Related]
18. Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial.
Pan H; Yu M; Tang X; Mao X; Liu M; Zhang K; Qian C; Wang J; Xie H; Qiu W; Ding Q; Wang S; Zhou W
Med; 2024 Apr; 5(4):291-310.e5. PubMed ID: 38417440
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Wei F; Huang Q; He J; Luo L; Zeng Y
Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab Plus Sorafenib
Liu Q; You N; Li J; Wu K; Peng X; Wang Z; Wang L; Zhu Y; Zheng L
Front Oncol; 2021; 11():694409. PubMed ID: 34737945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
